Dual-mode CRISPR system enables simultaneous on and off gene control

Turning genes on and off is like flipping a light switch, controlling whether genes in a cell are active. When a gene is ...

Intellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that longer-term data from the ...
TMCnet

Intellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (…

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine ...
Science Africa on MSN

AI System Developed to Automate Gene Editing Experiments

By Milliam MurigiInternational researchers have developed an artificial intelligence (AI) system dubbed CRISPR-GPT, designed to automate and enhance CRISPR-based gene-editing experiments.Clustered ...

Genetically engineered mice could take the bite out of Lyme disease on Nantucket, scientists say

Scientists hope genetically modified mice will curb the spread of Lyme disease. They headed to Nantucket — home to a large ...
The Chosun Ilbo on MSN

KAIST, Korea Research Institute Develop World's First Dual-Mode CRISPR

KAIST and the Korea Research Institute of Chemical Technology have jointly developed the world’s first new ‘CRISPR gene-editing technology (CRISPR)’ capable of simultaneously turning genes on and off.
Frontiers

Next-Generation Breeding Approaches Targeting Root System Architecture for Crop Resilience and Yield Improvement

Modern agriculture faces mounting challenges from climate change, soil degradation, and rising biotic and abiotic stresses, ...
Medscape

Gene-Edited Cells Alleviate Pain Crisis in Sickle Cell Disease

Exagamglogene autotemcel (exa-cel), a CRISPR/Cas9 gene-edited cell therapy, eliminated vaso-occlusive crises in 97% of ...

Crispr Therapeutics: Why Stock Fell On Q2 Earnings, And Why We're Now Back On Track

CRISPR Therapeutics AG is a long-term buy despite slow Casgevy uptake. Click for my updated look at CRSP earnings and the ...
News-Medical.Net

CRISPR-based tongue swab test shows promise for tuberculosis detection

Tulane University researchers have developed an enhanced CRISPR-based tuberculosis test that works with a simple tongue swab, ...

New Cas9 proteins dramatically lower the error rate of prime editing

A genome-editing technique known as prime editing holds potential for treating many diseases by transforming faulty genes into functional ones. However, the process carries a small chance of inserting ...

Landmark UCSF Study Demonstrates Functional Rescue of SCN2A Loss of Function, Underscoring the Potential of Regel Therapeutics' Targeted EpiEditing Platform.

CAMBRIDGE, Mass. and SAN FRANCISCO, Sept. 17, 2025 /PRNewswire/ -- The laboratories of Dr. Kevin Bender and Dr. Nadav Ahituv ...